SCHEMBL4425381

SCHEMBL4425381

NOP(=O)(CNS(=O)(=O)c1cccs1)Oc1cccc(Cl)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 1/20 0.43
CYP2C9 P11712 1/20 0.43
CYP2C19 P33261 1/20 0.43
MEN1 O00255 3/20 0.41
KMT2A Q03164 3/20 0.41
PKM P14618 1/20 0.41
ALDH1A1 P00352 3/20 0.41
MAPT P10636 4/20 0.41
SMN1; SMN2 Q16637 4/20 0.41
LMNA P02545 3/20 0.41
HTT P42858 1/20 0.41
RECQL P46063 1/20 0.41
CCR2 P41597 2/20 0.39
POLB P06746 1/20 0.39
CRHBP P24387 1/20 0.39
CRHR2 Q13324 1/20 0.39
TP53 P04637 1/20 0.39
NPC1 O15118 1/20 0.38
TSHR P16473 1/20 0.38
RAB9A P51151 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4419693 0.93 CYP2D6 (0.47) CYP2D6CYP2C9CYP2C19MEN1KMT2A
SCHEMBL4431913 0.88 CYP2D6 (0.46) CYP2D6CYP2C9CYP2C19MEN1KMT2A
SCHEMBL13885134 0.85 CYP2D6 (0.46) CYP2D6CYP2C9CYP2C19MEN1KMT2A
Ammonia Solution, Strong SCHEMBL4425384 0.84 CYP2D6 (0.45) CYP2D6CYP2C9CYP2C19MEN1KMT2A
SCHEMBL4430986 0.73 CYP2D6 (0.47) CYP2D6CYP2C9CYP2C19MEN1KMT2A
SCHEMBL4551954 0.72 CYP2D6 (0.58) CYP2D6CYP2C9CYP2C19MEN1KMT2A
Ammonia Solution, Strong SCHEMBL4431916 0.71 CYP2D6 (0.48) CYP2D6CYP2C9CYP2C19MEN1KMT2A
SCHEMBL6908900 0.70 CYP2D6 (0.46) CYP2D6CYP2C9CYP2C19PKMALDH1A1
SCHEMBL4430974 0.67 CYP2D6 (0.64) CYP2D6CYP2C9CYP2C19KMT2APKM
SCHEMBL4432236 0.65 CYP2C9 (0.55) CYP2D6CYP2C9CYP2C19ALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7514556-B2 Inhibitors of β-lactamase METHYLGENE INC. (CA) 2009-04-07 US disclosed
US-20070293675-A1 Novel Inhibitors Of Beta-Lactamase METHYLGENE, INC. (CA) 2007-12-20 US disclosed
US-7259172-B2 phenyl or thien-2-yl substituted amide methyl phosphonate or phosphonyl halide derivatives; do not require a beta -lactam pharmacophore; bactericides; antibiotic resistance METHYLGENE INC. (CA) 2007-08-21 US disclosed
US-20060105999-A1 Novel inhibitors of beta-lactamase METHYLGENE, INC. (CA) 2006-05-18 US disclosed
US-7030103-B2 Sulfonamidomethyl phosphonate inhibitors of β-lactamase METHYLGENE, INC. (CA) 2006-04-18 US disclosed
EP-1194436-B1 SULFONAMIDOMETHYL PHOSPHONATE INHIBITORS OF BETA-LACTAMASE METHYLGENE INC (CA) 2005-11-30 EP disclosed
US-6921756-B2 Inhibitors of β-lactamase METHYLGENE, INC. (CA) 2005-07-26 US disclosed
US-6884791-B2 Inhibitors of β-lactamase METHYLGENE, INC. (CA) 2005-04-26 US disclosed
US-20050043276-A1 Novel inhibitors of beta-lactamase METHYLGENE, INC. (CA) 2005-02-24 US disclosed
WO-2004048393-A2 NOVEL INHIBITORS OF β-LACTAMASE METHYLGENE, INC. (CA) 2004-06-10 WO disclosed
US-20040082546-A1 Novel Inhibitors of beta-lactamase METHYLGENE, INC. 2004-04-29 US disclosed
US-20040059115-A1 Novel sulfonamidomethyl phosphonate inhibitors of beta-lactamase 92229129 QUEBEC INC. (CA) 2004-03-25 US disclosed
US-20040029836-A1 Novel inhibitors of beta-lactamase 92229129 QUEBEC INC. (CA) 2004-02-12 US disclosed
US-6472406-B1 Sulfonamidomethyl phosphonate inhibitors of beta-lactamase METHYLGENE, INC. (CA) 2002-10-29 US disclosed
EP-1194436-A1 SULFONAMIDOMETHYL PHOSPHONATE INHIBITORS OF BETA-LACTAMASE Methylgene, Inc. (CA) 2002-04-10 EP disclosed
WO-2001002411-A1 SULFONAMIDOMETHYL PHOSPHONATE INHIBITORS OF β-LACTAMASE METHYLGENE INC. (CA) 2001-01-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050043276-A1 Novel inhibitors of beta-lactamase MGAM, LSS, CYP51A1 CYP2D6 335/4885CYP2C9 493/4885CYP2C19 410/4885
US-20040029836-A1 Novel inhibitors of beta-lactamase LSS, MGAM, COASY CYP2D6 384/4885CYP2C9 578/4885CYP2C19 499/4885
US-20060105999-A1 Novel inhibitors of beta-lactamase LSS, MGAM, LCT CYP2D6 384/4885CYP2C9 580/4885CYP2C19 531/4885
US-20040059115-A1 Novel sulfonamidomethyl phosphonate inhibitors of beta-lactamase PGLS, MGAM, STS CYP2D6 886/4885CYP2C9 1663/4885CYP2C19 1296/4885
US-20070293675-A1 Novel Inhibitors Of Beta-Lactamase MGAM, LSS, CYP51A1 CYP2D6 335/4885CYP2C9 493/4885CYP2C19 410/4885
US-20040082546-A1 Novel Inhibitors of beta-lactamase LSS, MGAM, COASY CYP2D6 298/4885CYP2C9 465/4885CYP2C19 443/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.